STE:NYE-STERIS plc (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 230.6

Change

-2.15 (-0.92)%

Market Cap

USD 5.64B

Volume

0.66M

Analyst Target

USD 175.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

STERIS PLC is a provider of infection prevention and other procedural products and services, focused on healthcare, pharmaceutical and research.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.23 (+0.22%)

USD 179.96B
SYK Stryker Corporation

+1.96 (+0.57%)

USD 131.96B
BSX Boston Scientific Corp

-0.20 (-0.26%)

USD 113.42B
MDT Medtronic PLC

-0.62 (-0.76%)

USD 106.70B
EW Edwards Lifesciences Corp

-0.38 (-0.43%)

USD 52.43B
PHG Koninklijke Philips NV ADR

-0.22 (-0.85%)

USD 24.63B
ZBH Zimmer Biomet Holdings Inc

+0.22 (+0.21%)

USD 22.20B
SONVF Sonova Holding AG

N/A

USD 19.66B
SONVY Sonova Holding AG

-1.49 (-2.34%)

USD 19.16B
SNN Smith & Nephew SNATS Inc

-0.37 (-1.44%)

USD 11.07B

ETFs Containing STE

HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

-0.03 (0%)

CAD 0.05B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.89% 65% D 53% F
Dividend Return 0.24% 43% F 10% F
Total Return 5.13% 65% D 49% F
Trailing 12 Months  
Capital Gain 14.23% 63% D 59% D-
Dividend Return 1.01% 43% F 11% F
Total Return 15.23% 63% D 53% F
Trailing 5 Years  
Capital Gain 71.07% 79% B- 77% C+
Dividend Return 6.36% 38% F 20% F
Total Return 77.43% 84% B 75% C
Average Annual (5 Year Horizon)  
Capital Gain 11.95% 71% C- 74% C
Dividend Return 12.89% 71% C- 72% C
Total Return 0.94% 44% F 23% F
Risk Return Profile  
Volatility (Standard Deviation) 18.87% 94% A 59% D-
Risk Adjusted Return 68.31% 97% N/A 88% B+
Market Capitalization 5.64B 79% B- 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.50 59% 15%
Price/Book Ratio 3.14 42% 28%
Price / Cash Flow Ratio 23.62 33% 13%
Price/Free Cash Flow Ratio 16.84 44% 20%
Management Effectiveness  
Return on Equity 8.92% 81% 53%
Return on Invested Capital 9.21% 85% 63%
Return on Assets 5.09% 85% 73%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.